157 related articles for article (PubMed ID: 24457564)
1. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
Safra T; Rogowski O; Muggia FM
Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
[TBL] [Abstract][Full Text] [Related]
2. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
3. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
4. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
Safra T; Grisaru D; Inbar M; Abu-Abeid S; Dayan D; Matceyevsky D; Weizman A; Klausner JM
J Surg Oncol; 2014 Nov; 110(6):661-5. PubMed ID: 24962381
[TBL] [Abstract][Full Text] [Related]
5. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Labidi-Galy SI; de La Motte Rouge T; Derbel O; Wolfer A; Kalbacher E; Olivier T; Combes JD; Heimgartner-Hu K; Tredan O; Guevara H; Heudel PE; Reverdy T; Bazan F; Heinzelmann-Schwarz V; Fehr M; de Castelbajac V; Vaflard P; Crivelli L; Bonadona V; Viassolo V; Buisson A; Golmard L; Rodrigues M; Ray-Coquard I
Gynecol Oncol; 2019 Nov; 155(2):262-269. PubMed ID: 31604666
[TBL] [Abstract][Full Text] [Related]
6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
7. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
8. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
9. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
[TBL] [Abstract][Full Text] [Related]
10. BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.
Zikan M; Vecerova L; Dubova O; Sehnal B; Soukupova J
J Cancer Res Ther; 2023; 19(3):684-687. PubMed ID: 37470594
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
13. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
14. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
[TBL] [Abstract][Full Text] [Related]
15. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Kwa M; Edwards S; Downey A; Reich E; Wallach R; Curtin J; Muggia F
Ann Surg Oncol; 2014 May; 21(5):1468-73. PubMed ID: 24081797
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
18. BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
Kotsopoulos J; Willows K; Trat S; Kim RH; Volenik A; Sun P; Narod SA; Boyd J; May T
Int J Gynecol Cancer; 2018 Jan; 28(1):69-76. PubMed ID: 29194191
[TBL] [Abstract][Full Text] [Related]
19. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
Hyman DM; Zhou Q; Arnold AG; Grisham RN; Iasonos A; Kauff ND; Spriggs D
Gynecol Oncol; 2011 Nov; 123(2):196-9. PubMed ID: 21855118
[TBL] [Abstract][Full Text] [Related]
20. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
Nicoletto MO; Bertorelle R; Borgato L; De Salvo GL; Artioli G; Lombardi G; Zustovich F; Marcato R; Parenti A; Montagna M; Donach ME
Int J Gynecol Cancer; 2009 Aug; 19(6):1022-8. PubMed ID: 19820363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]